Bessemer Group Inc. Increases Stock Position in Pfizer Inc. (NYSE:PFE)

Bessemer Group Inc. lifted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 11.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 132,478 shares of the biopharmaceutical company's stock after acquiring an additional 13,228 shares during the period. Bessemer Group Inc.'s holdings in Pfizer were worth $3,358,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. Rialto Wealth Management LLC purchased a new stake in Pfizer during the fourth quarter valued at about $26,000. Clarity Asset Management Inc. purchased a new position in Pfizer during the 4th quarter valued at about $27,000. Gould Capital LLC increased its holdings in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC purchased a new position in Pfizer during the 4th quarter valued at about $28,000. Finally, Bernard Wealth Management Corp. purchased a new position in Pfizer during the 4th quarter valued at about $30,000. Institutional investors own 68.36% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on PFE. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Cantor Fitzgerald began coverage on Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. UBS Group boosted their price target on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Stock Down 0.2%

Shares of PFE traded down $0.04 during mid-day trading on Friday, reaching $24.20. The company had a trading volume of 39,502,107 shares, compared to its average volume of 41,339,880. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The firm has a 50-day moving average price of $23.46 and a 200 day moving average price of $24.85. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The company has a market capitalization of $137.56 billion, a price-to-earnings ratio of 17.53, a price-to-earnings-growth ratio of 0.88 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. During the same period in the previous year, the firm posted $0.82 EPS. The business's revenue for the quarter was down 7.8% compared to the same quarter last year. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.11%. Pfizer's dividend payout ratio is currently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.